Start
•
Completion

Study of Ketamine as an Antidepressant in Major Depressive Disorder

Unknown statusRegisteredCTG

Single-group, Phase I–II study (n=35) evaluating a single IV ketamine infusion (0.5 mg/kg over 40 minutes) with four-hour monitoring in adults with major depressive disorder.

Details

Open single-group treatment study administering a single IV infusion of ketamine hydrochloride 0.5 mg/kg over 40 minutes with four hours of post-infusion monitoring.

Primary outcomes assess changes in neuroimaging and biochemical measures; secondary outcomes include depressive and manic symptoms, global psychiatric change, and suicidal ideation.

Topics:Major Depressive Disorder (MDD)

Registry

Registry linkNCT01573741